An LPAR1 antagonist, BMS-986020 from Bristol Myers Squibb, is in phase 2 clinical trials, (NCT01766817) against IPF too, although this inhibitor has caused an increase in hepatic enzymes [78]. Here, LPAR1 is linked to idiopathic pulmonary fibrosis.